Two years ago, Amgen purchased the marketing rights to Celgene’s psoriasis pill Otezla for $13.4 billion. At that time, the company most likely did not think it would have to compete against Sandoz and Zydus Pharmaceutical in the generics market any time soon. And now, thanks to a win in court, Amgen appears poised to enjoy several more years of exclusivity in the key U.S. market.
Click here to read the entire article.